Table 1

Patient characteristics

Patient

Age (years)/sex

Disease duration (years)

Treatment


1

54/M

5

Azathioprine, methylprednisolone

2

38/F

6

Hydroxychloroquine, salazopyrine

3

64/F

7

NSAID

4

43/F

5

NSAID

5

46/M

1

Salazopyrine

6

46/M

<1

Salazopyrine

7

52/M

11

NSAID

8

53/F

11

NSAID

9

49/M

10

NSAID

10

52/F

4

NSAID

11

69/F

36

Salazopyrine

12

65/F

<1

Untreated

13

35/M

<1

Untreated

14a

57/F

4

Methotrexate

15a

46/M

2

Anti-TNF, salazopyrine

16a

41/M

10

Salazopyrine

17a

41/M

13

Methotrexate

18a

60/M

2

Leflunomide

19a

43/F

5

Methotrexate

20b

63/M

17

Salazopyrine

21a,b

65/F

4

Salazopyrine, hydroxychloroquine

22b

62/F

12

Leflunomide

23b

54/F

17

Methylprednisolone


aSynovial fluid sample. bSynovial tissue sample. F, female; M, male; NSAID, nonsteroidal anti-inflammatory drug; TNF, tumour necrosis factor.

Linsen et al. Arthritis Research & Therapy 2005 7:R493-R502   doi:10.1186/ar1695

Open Data